Insulin pen HumaPen Savvio launched in India
The insulin pen for diabetes, developed by Eli Lilly and Boehringer Ingelheim, has a shelf life of six years
Mumbai: The Indian units of foreign drug makers Eli Lilly and Co. and Boehringer Ingelheim GmbH (BI) jointly introduced a new insulin pen on Tuesday in India’s fast-growing market for diabetes therapies.
The new insulin delivery device, HumaPen Savvio, has been designed to resemble a small personal accessory rather than a medical device, according to a joint statement by the companies.
HumaPen Savvio was invented by Eli Lilly and has an extended shelf life of up to six years after first use. An existing Lilly-BI alliance in India will co-market the product. This is the second product to be jointly marketed by the this alliance in India. It launched an anti-diabetic drug, Trajenta, last year.
Diabetes continues to be a serious health issue in India. Current estimates by the drug industry indicate that 63 million adults in India suffer from the lifestyle disease.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!